

Transgender sexual and reproductive health: a systematic review



Sílvia Martins Fernández,¹ Alexandra Martins Pimentel,² Raquel Araújo Almeida³

RESUMO

Background: The right to access safe and high-quality sexual and reproductive healthcare is part of the well-being of all people. There is a scarcity of clinical guidelines regarding transgender (TG) specific family planning.

Objective: This synthesis of information intends to describe the approach towards the TG population's sexual health.

Methods: A comprehensive search was conducted in the MEDLINE and Scopus databases, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement. The quality of retrieved studies was assessed using the Critical Appraisal Skills Programme Qualitative Checklist for qualitative studies and an adapted version of the Quality Assessment Tool for Cross-Sectional Studies. The protocol was registered on PROSPERO (CRD42022371962).

Results: From the 671 articles retrieved, 13 fulfilled the predefined inclusion and exclusion criteria, and were selected to perform the in-depth analysis. Phenomena of interest were subdivided into patient and provider-level issues, contraception, fertility preservation, and cancer screening. Contraception can have many purposes, including the prevention of pregnancy, and frequently exerts an impact on gender dysphoria. A great percentage of TG patients believe that testosterone may be used as a contraceptive method, which prevents recognition of their pregnancy risk. Providers' lack of formal education plus the discrimination TG people face contribute to the rising of myths and misinformation among the population. Most TG people desire to be parents, but the question of whether biologically or not is mostly undefined. TG people do not routinely undertake pelvic examinations or PAP smears.

Conclusion: The present review outlines the urge to develop guidelines for TG sexual and reproductive health. Primary care doctors are vital in managing TG people's health concerns.

Keywords: Family planning; Reproductive health; Primary health care; Transgender persons.

INTRODUCTION

According to the World Health Organization (WHO), ensuring access to safe, affordable, high-quality sexual and reproductive health services and information is a right and is part of the well-being of all people.¹ The term transgender (TG) refers to people whose gender identity differs from their sex assigned at birth.² This concept is an umbrella term that encircles a broad range of individuals with varying identities, gender expressions, experiences, and needs.³ It includes individuals who identify as male or

female as well as those who position their gender identity as non-binary.⁴

In the FRA 2019 LGBTI survey, in which 20,933 TG people participated, 28% self-identified as transgender women (TGF), 21% as transgender men (TGM), and 51% as non-binary.⁵ According to data published in June 2022, over 1,6 million adults (ages 18 and older) and youth (ages 13 to 17) identify as TG in the United States of America, of which 0.6% were ages 13 and older. Of the 1,3 million adults who identify as TG, 38.5% are TGF, 35.9% are TGM, and 25.6% are gender nonconforming.⁶

In June 2021, the European Parliament called for inclusive sexual and reproductive health (SRH) rights and sex education to make trans-specific healthcare accessible and reimbursed across the European Union (EU), reaffirmed its call to ban non-medically necessary

1. Médica Interna de Medicina Geral e Familiar. USF São Neutel. Chaves, Portugal.

2. Médica Interna de Medicina Geral e Familiar. USF Garcia de Orta. Porto, Portugal.

3. Médica Interna de Medicina Geral e Familiar. USF Alves Martins. Viseu, Portugal.


TABLE 1. Search strategy details

DATABASE	QUERY
PubMed	((((((((((("Family Planning Services"[Mesh]) OR "Reproductive Health Services"[Mesh]) OR "Sex Education"[Mesh]) OR ("Contraception"[Mesh] OR "Health Services Accessibility"[Mesh])) AND ("Transgender Persons"[Mesh] OR "Health Services for Transgender Persons"[Mesh])) NOT "HIV"[Mesh]) NOT "Review" [Publication Type]) NOT "Systematic Review" [Publication Type]) NOT "Meta-Analysis" [Publication Type]) NOT "Editorial" [Publication Type]) NOT "Case Reports" [Publication Type])
Scopus	TITLE-ABS-KEY (("Family Planning Services") OR ("Reproductive Health Services") OR ("Sex Education") OR ("Contraception") OR ("Health Services Accessibility")) AND TITLE-ABS-KEY (("Transgender Persons") OR ("Health Services for Transgender Persons")) AND NOT TITLE-ABS-KEY (("HIV") OR ("Pre-Exposure Prophylaxis"))) AND (LIMIT-TO (DOCTYPE , "ar")

surgeries and treatment on intersex infants and children, and called for banning sterilization requirements across the EU.⁶ Even though Portugal had already established a model of intervention to be implemented by healthcare providers in matters related to gender identity and sexual characteristics of persons in 2018, no national guidelines or recommendations have been issued. Providers are expected to follow the Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, version 7, of the World Professional Association for Transgender Health.⁷

In Portugal, as in many other European countries, medical doctors, nurses, and other healthcare providers may conclude their formative curricula without ever contacting resources related to LGBTQIA+ issues and without receiving even basic training on that matter.⁸ The lack of specific knowledge, coupled with social bias, constitutes a major factor in the reproduction of compulsory cis-heteronormativity, invisibility, and, ultimately, discrimination.⁸

Aim of the study

This systematic review aimed to approach sexual and reproductive health regarding TG populations. Data from peer-reviewed scientific literature was reviewed to define the *leges artis* of TG people's sexual health, which includes aspects such as contraception, family planning, and reproductive health as a whole.

METHODS

Search strategy

This review was performed in keeping with the Preferred Reporting Items for Systematic Reviews and

Meta-Analyses (PRISMA) statement.⁹ The protocol was registered in the PROSPERO International Prospective Register of Systematic Reviews (CRD42022371962).

Two different databases, MEDLINE and Scopus, as specified in Table 1, were explored. Search terms were refined and adapted to each database. The search included publications published before the 24th of March of 2023, and no time or language restrictions were imposed.

Inclusion and exclusion criteria

To be included in this systematic review, original studies had to assess sexual and reproductive health interventions in TG populations. There were no limits imposed on the gender, age, or race of the population included. When considering health interventions, papers must have included well-defined sexual health interventions on a primary care basis (such as contraception, family planning, and sex education as a whole).

Case reports, reviews, meta-analyses, and editorial letters were excluded. Publications that did not substantively relate to the purpose of the current review were excluded.

The authors decided to exclude the topic of human immunodeficiency virus (HIV) infection from the review due to the great amount of literature on the topic and pre-existing systematic reviews with meta-analysis.

Study selection

In the screening and inclusion round, two independent authors examined each title/abstract and full text (respectively), and disagreements between reviewers were resolved by referral to a third reviewer.




Figure 1. Screening process.

Data was extracted by authors using a predesigned data extraction form. At each step of data extraction, any discrepancies were resolved through discussion. The form included: the article name, author(s), publication date, journal of publication, study design, general subject, sample size, sexual and reproductive health interventions described, results, and limitations.

Study quality assessment

Three review authors independently assessed the quality of the papers using the Critical Appraisal Skills Programme (CASP) Qualitative Checklist for qualitative stu-

dies and the Quality Assessment Tool for Cross-Sectional Studies adapted to fit a transversal study design.¹⁰⁻¹¹

RESULTS

Study design

The inquiry included publications before the 24th of March of 2023, without any time or language restrictions, resulting in 671 articles retrieved. After removing duplicates, 512 studies were left for abstract analysis, of which 79 were selected. The full text of these articles was thoroughly analysed and 13 fulfilled the predefined inclusion criteria. The screening process is shown in Figure 1.


TABLE 2. Characteristics of reports included

Author (year)	Study design	Phenomena of interest	Population (%TG/ providers)
Agénor et al. (2020)	Qualitative	Contraception	21 (90.5%TGM)
Chen et al. (2019)	Cross-sectional	SRH provider knowledge	202 (43.1% Physicians)
Cipres et al. (2017)	Cross-sectional	Contraception	26 (100%TGM)
Fix et al. (2020)	Qualitative	SRH provider knowledge	27 (22%TGM)
Forsberg and Eliason (2022)	Qualitative	SRH provider knowledge	20 (55%TG)
Gomez et al. (2020)	Qualitative	Contraception	20 (65%TGM)
Light et al. (2018)	Cross-sectional	Contraception	196 (33.7%TGM)
Nahata et al. (2020)	Cross-sectional	Contraception, fertility preservation	44 (91%TG)
Rahman et al. (2019)	Cross-sectional	Preventive care, knowledge	148 (24%TGF, 18.2%TGM)
Reynolds and Charlton (2021)	Cross-sectional	Contraception	185,289 (1.6%TG)
Stark et al. (2019)	Mixed methods	Contraception and family planning	150 (100%TGM)
Tishelman et al. (2019)	Qualitative	SRH provider knowledge	225 (17.2% Physicians)
Vyas et al. (2021)	Cross-sectional	Fertility preservation	397 (TGF 12.3%, TGM 19.1%)

Legend: SRH = Sexual and reproductive health; TG = Transgender; TGM = Transmasculine; TGF = Transfeminine.

Although some studies were not included in the analysis, they provided useful information to the discussion of this paper.¹²⁻¹⁵

As illustrated in Table 2, six studies had a qualitative design and eight were cross-sectional. The number of patients in each study sample varied from 21 to 185,289 patients and, overall, 186,765 participants were included.

Quality assessment

Quality assessment results are depicted in Tables 3 and 4. The Critical Appraisal Skills Programme (CASP) Qualitative Checklist for qualitative studies and the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies were used.¹⁰⁻¹¹

Most of the studies punctuated YES (Y) on the most relevant endpoints.

Main outcomes

Patient-level issues

Contraception

Patients' convictions and preferences regarding contraception were related to a fundamental lack of information and support regarding method choice.¹⁶

Forsberg and colleagues stated three main reasons why TG patients do not bring up contraception at doctors' appointments: experiences of trauma in health-care environments or other settings, gender dysphoria, sexual fluidity, and gendered care. Additionally, the perception that most clinicians lack fundamental knowledge about SRH in the TG population directly impacts the patient's willingness to broach this subject.¹⁷ Another study suggested that, although half of the patients were not sure if they were offered contraceptive options from their healthcare provider, the majority (75%) were satisfied with the amount of information provided.¹⁸

According to Cipres et al., half of the study sample were *at-risk* for pregnancy and desired to avoid pregnancy. Being 'at risk' for pregnancy was defined as having a uterus and reporting receptive vaginal sex with a cisgender man or TG woman in the prior year. Patients' gender dysphoria, as well as the misconception that testosterone may be used as a contraceptive method, impedes some TG patients from recognizing their pregnancy risk.^{17,19}

Despite the possibility of pregnancy, few participants reported the use of an effective contraceptive method, and many used no method, although another study


TABLE 3. CASP Qualitative Checklist (Y = Yes, N = No; CT = Cannot Tell)

	Agénor et al. (2020)	Fix et al. (2020)	Forsberg and Eliason (2022)	Gomez et al. (2020)	Stark et al. (2019)	Tishelman et al. (2019)
Was there a clear statement of the aims of the research?	Y	Y	Y	Y	Y	Y
Is a qualitative methodology appropriate?	Y	Y	Y	Y	Y	Y
Was the research design appropriate to address the aims of the research?	N	N	N	N	N	N
Was the recruitment strategy appropriate to the aims of the research?	N	Y	Y	Y	Y	Y
Was the data collected in a way that addressed the research issue?	Y	Y	Y	Y	Y	Y
Has the relationship between researcher and participants been adequately considered?	Y	Y	N	Y	CT	CT
Have ethical issues been taken into consideration?	Y	Y	N	Y	Y	Y
Was the data analysis sufficiently rigorous?	Y	Y	Y	Y	Y	Y
Is there a clear statement of findings?	Y	Y	Y	Y	Y	Y

revealed that most patients' providers offered options to prevent sexually transmitted infections (STIs) and pregnancy (80%; 85%, respectively).¹⁸

Reasons cited for preferring one contraceptive method to another were the desire to prevent pregnancy, menstrual period management, and the impact of the method on their gender dysphoria.^{16,20} For TGM, being pregnant may feel incongruent with their masculine gender identity or expression and could potentially increase feelings of gender dysphoria.²¹

The contraceptive methods reported by participants versus the methods recommended by providers were similar. TG people chose primarily the condom as a method of contraception, followed by the pill and IUD.^{16,22-23} Gender minorities have lower odds of using any contraceptive method, but have higher odds of using long-acting reversible contraception (implants, intrauterine devices). Specifically, TGM students had higher odds

of using sterilization and *other* contraceptive methods such as the male condom, the diaphragm, and fertility awareness-based methods.²¹

Even though most of the TG population uses contraception, some characteristics, such as being a student, having socially affirmed one's gender, and having a partner, are linked to a diminished current contraceptive use.^{20,23} On the other hand, a greater number of sex partners is linked to an increased current contraceptive use. Beyond contraception use, social support decreased the odds of lifetime pregnancy.²⁰

Many individuals expressed concern about using hormonal contraceptives out of fear of possible interactions between oestrogen and testosterone, and potential unwanted feminizing effects.^{16-17,20,22}

One of the most frequently raised questions by study participants was if testosterone can be used as contraception.²⁰ Patients desired better data on the impact


TABLE 4. Quality Assessment Tool for Cross-Sectional Studies (Y = Yes, N = No; NA = Not Applicable)

	Chen et al. (2019)	Cipres et al. (2017)	Light et al. (2018)	Nahata et al. (2020)	Rahman et al. (2019)	Reynolds and Charlton (2021)	Stark et al. (2019)	Vyas et al. (2021)
Was the research question or objective in this paper clearly stated?	Y	Y	Y	Y	Y	Y	Y	Y
Was the study population clearly specified and defined?	Y	Y	Y	Y	Y	Y	Y	Y
Was the participation rate of eligible persons at least 50%?	NA	NA	N	Y	Y	Y	NA	NA
Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	Y	Y	Y	Y	Y	Y	Y	Y
Was a sample size justification, power description, or variance and effect estimates provided?	N	N	N	N	N	Y	Y	N

of testosterone on fertility and SRH, specifically on dosage, length of treatment, and pregnancy potential after cessation of testosterone.²²

Agénor et al. ascertained that most participants recognized that testosterone is ineffective as contraception and clinically proven methods were necessary for pregnancy prevention.¹⁶ On the other hand, in a study with 20 participants, 12 believed that testosterone use reduced their likelihood of becoming pregnant as a result of the belief that testosterone use may cause sterility.²² A separate study found that thirty participants (16%) used testosterone as a contraceptive method, a third of which had been advised by healthcare providers to do so.²³

Fertility Preservation

Most TG people desired to become parents.^{10,23-24} They indicated primary care doctors and endocrinologists as their primary sources of information surrounding fertility preservation (FP).^{18,23-25} Nevertheless, a third of patients stated that medical professionals did not adequately address their FP goals or did not ask about their fertility desires. One-third of patients would

be interested in a consultation with a reproductive endocrinologist if offered.²³⁻²⁴

Referred barriers for FP were mainly the cost of treatment, discontinuation/delay of hormonal therapy, or worsening of gender dysphoria with treatment/pregnancy.²³⁻²⁵ Even though becoming a parent is a frequent desire, 66% of TG people had no intention to pursue FP, and about 12% desired to do so.²⁴

Twenty percent of TG people would state that having biologically related children was important, versus 43% who did not. Adoption was only considered by 17%, and 40% did not contemplate adoption.²⁴ Indeed, *not caring to have* a biological child, followed by being *too young* were the most common reasons for declining FP.¹⁸ Desire for fertility preservation was not influenced by any individual factors, including gender identity, race/ethnicity, or age.²⁴

Two to six percent of TG patients requested a referral for FP. Additionally, 3% had undergone FP, the majority of whom had performed sperm cryopreservation. Furthermore, Vyas et al. analysed the decisional regret considering FP in TG individuals. Decisional regret was



moderate to severe among those who had not yet undergone FP and were unsure if they would. A firm decision to pursue or not pursue fertility treatment was associated with mild decisional regret.²⁴

Cervical cancer screening and prevention

According to Rahman et al., TG people had access to a primary care physician akin to cisgender people, nevertheless only a minority had seen a gynaecologist compared to ciswomen. TGM and TGF had significantly less correct knowledge about HPV, and only 9% of TGF had received the HPV vaccine. One-third of TGM had never received a pelvic examination or cervical Pap smear in their lifetime. Abnormal cervical results were received in 15% of TGM and 24% had contracted STIs within the past year. Additionally, herpes differentially impacted ciswomen, with no reported cases in TG.²⁶

Provider-level issues

In a study involving physicians, psychologists, master-level mental health providers, and non-physician health-care providers (all providing care to TG individuals), it was determined that overall fertility-related knowledge was high. The level of knowledge was comparable among the different types of providers, although physicians were most likely to discuss fertility with patients.²⁷

Providers recognized that lack of education (with education mostly based on information from conferences, word of mouth, and trial and error), provider discomfort, judgments or assumptions, and the need for trauma-informed healthcare have impacted their pregnancy prevention care practices.¹⁷

One study discussed providers' fear of offending patients and nervousness around addressing pregnancy prevention care with TG patients.¹⁷

Fix et al. outlined the perspectives of several SRH providers concerning contraceptive methods. Providers suggested that the alleviation of dysphoria, amenorrhea and being free of hormones are the most valuable characteristics to patients.²⁸

Several strategies were highlighted as a means to improve SHR care in the TG population, such as the development of educational materials and their dissemination, collaborating with the TG population to better cater to their needs, and developing specific training for healthcare providers in these matters.²⁸

DISCUSSION

This systematic review is the first to summarize the evidence on the sexual and reproductive health of TG people.

Few guidelines are aimed at providing primary care practitioners with tools and knowledge to meet the needs of TG patients. Colleagues from the University of California, San Francisco created the Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People. They thoroughly explored issues regarding hormone therapy, comorbidities, cancer screening, and surgical planning, but nothing regarding contraception in this special population.²⁹

First and foremost, contraception in TG people can have many purposes, including the prevention of pregnancy, and frequently exerts an impact on the gender dysphoria and psychological distress experienced by TGM as menarche occurs, as this is the primary manifestation affirming that their body does not function according to their gender identity.³⁰ Consequently, health providers should be able to acknowledge the diverse psychological factors involved in contraception choice, such as gender dysphoria, but also the fear of getting pregnant.

To address those issues, TGM need to be aware that they are *at risk* of being pregnant. A great percentage of TG patients still believe that testosterone may be used as a contraceptive method, which prevents the recognition of their pregnancy risk.¹⁷ Therefore, primary care providers need to be prepared to counsel and prescribe the best contraceptive methods, adequate to the individuality of each patient, but also to educate TGM about family planning.²³

A recent study determined that TG youth gathered SRH information from school, providers, peers, romantic partners, and online sources. It was ascertained that school curricula were not sufficiently adapted to fit TG sexual education needs, and some important topics were suggested: gender dysphoria, gender-affirming interventions, fertility, and contraception.¹²

Contraception in TGM covers a wide range of methods, from condoms, and birth control pills to IUDs. To effectively counsel TGM, better data is needed on the minutiae of the different birth control pills (to alleviate gender dysphoria), the impact of testosterone on fertility, and the effects of low-dose contraceptive hormones on exogenous testosterone use.²³



The lack of formal education among providers plus the discrimination TG people face contributes to the rising of myths and misinformation among the population. These beliefs influence contraceptive and SRH care experiences, mostly negatively, although the intention of avoiding pregnancy is maintained.^{16-17,19}

Steps should be taken to improve sexual health curricula in schools and medical faculties, mitigating the misinformation that drives the contraceptive choices of the population, particularly in TG communities.

Fertility preservation should be an integral part of an SRH consult. Most TG people desire to be parents, but the question of whether biologically or not is mostly undefined. Surprisingly, during the transition process, only a minority of patients were referred to an endocrinologist. On the other hand, some TG people consider themselves too young or *do not care* about being parents. This disconnection may be explained by a focus on the transition at the time, in detriment to reproductive planning.²⁴⁻²⁵ When analysing the decisional regret scale towards fertility, TG people who were interested in a consultation with a reproductive endocrinologist expressed moderate-to-severe regret. This was associated with higher decisional conflict, lower satisfaction with a decision, fear of adverse physical health outcomes, and greater anxiety levels.³¹

Indeed, a study revealed that 37.5% of TGM would have considered cryopreservation of gametes had the technique been available during transition.³² Vyas et al. inferred that consultation with a fertility specialist may decrease decisional regret.²⁴ A reproductive endocrinologist may be able to provide more detailed counselling and consequently allow TG to make a conscious and informed decision surrounding fertility preservation.

Cervical cancer screening and prevention should be part of the standard care of any individual identifying as female or who was born as a female. Nevertheless, TG people do not routinely undertake pelvic examinations or Pap smears.

Two factors seem to increase the prevalence of physical examination of the TG population: on one hand, having access to a gynaecologist, and on the other hand, perception of the importance of HPV screening. The paucity of knowledge about HPV among TG people needs to be addressed, allowing for the rise of HPV immunization, and genital screening and, ultimately, rai-

sing awareness about the importance of SRH consults. Additionally, previous negative experiences may influence TGM's willingness to ask for or receive a cervical Pap smear or pelvic examination.³³

No papers were retrieved about breast and prostate cancer in the TG population, even though this is a major concern for patients and doctors alike.

In the Portuguese paradigm, HPV screening and pelvic examination are mainly performed by primary care physicians – following the organized populational screening.³⁴ This greatly contrasts with other regions, where HPV screening almost exclusively depends on secondary care.

By their (almost) all-encompassing reach to the community, family doctors are in a privileged position to offer cancer screening to minority populations (including TGM), which present with most invasive cervical cancers.³⁵⁻³⁷

Primary care physicians must be mindful of the healthcare barriers and discrimination in screening for cancer in TGM. Delay in diagnosis and treatment occurs if the screenings are not executed at the right time. Even if patients have undergone gender confirmation surgery, there is a residual malignant risk related to their assigned sex at birth.¹³

According to Giffort et al., healthcare providers avoid some SRH conversations with TG people for many reasons, such as the lack of formal education and clinical guidelines as well as misguided beliefs about pregnancy risk.³⁸

In a survey of general internal and family medicine clinicians, it was ascertained that the majority were willing to provide routine care and cervical cancer screening tests to TGM. It was observed that this willingness to provide care decreased significantly with age and the willingness to provide cervical cancer screening was higher among family physicians and those who had met a TG person. Although promising, these findings demonstrate that age, personal experiences, and biases affect doctors' willingness to provide care to the TG population. Ideally, every doctor should be willing to provide routine care to all patients – including those who identify as TG.¹⁵

Clinical practice guidelines with specific indications towards the TG population are needed, allowing for inclusive care and cancer screening in the TG population.

Regarding STIs, a recent scoping review revealed that only 14% of 700 existing articles concerning the TG population focused on sexual health, and HIV is by far the



best-studied infection, with 96% of articles reporting only laboratory results.³⁹⁻⁴⁰ Additionally, most research papers exclusively address sexual risk behaviours among TG people.

Indeed, when considering non-HIV STIs such as chlamydia, gonorrhoea, syphilis, viral hepatitis, and herpes simplex virus, the data is mainly self-reported. Consequently, it is difficult to know their true prevalence. Again, the need for specific STI screening guidelines and awareness among TG is reiterated.

Strengths and limitations

This systematic review is the first to summarize the evidence on the sexual and reproductive health of TG people. This review has comprehensively synthesized and analysed in depth 13 cross-sectional and qualitative studies, following Cochrane guidance and PRISMA statement to ensure the methodology was robust and systematic. Evidence was summarized and its quality evaluation was based on validated instruments.

There are some limitations to consider in this study. The results of this review may have been affected by selection and recall bias affecting the included papers. The authors have also identified aspects concerning recruitment methods, sample size, participant demographics and race/ethnicity, TG representation, and the self-reported character of data in the included publications as important limitations. It may also be argued that the interventions described do not reflect the full range of services available to the TG population.

Further research

This systematic review outlines the need to develop guidelines for TG sexual and reproductive health, where the diverse aspects of contraception are considered. Across the included studies, the authors specifically point out the need for research on contraceptive methods, pregnancy prevention counselling, the impact of testosterone therapy on contraception, and cancer and STI screening among TG people.

CONCLUSION

Family doctors are the first point of contact within the healthcare system, connected with the entire population from birth until death and, as such, are in a privileged position to provide care to disadvantaged po-

pulations. Considering secondary care has limited reach to the TG population, primary care assumes a vital role in the management of their health concerns.

REFERENCES

1. World Health Organization. Sexual health, human rights and the law. Geneva: WHO; 2015.
2. Bonnington A, Dianat S, Kerns J, Hastings J, Hawkins M, De Haan G, et al. Society of Family Planning clinical recommendations: Contraceptive counseling for transgender and gender diverse people who were female sex assigned at birth. *Contraception*. 2020;102(2):70-82.
3. Davidson M. Seeking refuge under the umbrella: inclusion, exclusion, and organizing within the category Transgender. *Sex Res Social Policy*. 2007;4:60.
4. Van Caenegem E, Wierckx K, Elaut E, Buysse A, Dewaele A, Van Nieuwerburgh F, et al. Prevalence of gender nonconformity in Flanders, Belgium. *Arch Sex Behav*. 2015;44(5):1281-7.
5. Calderon-Cifuentes PA. Trans discrimination in Europe: a TGEU analysis of the FRA LGBTI survey 2019 [homepage]. TGEU; 2021. Available from: <https://tgeu.org/tgeu-report-on-trans-discrimination-in-europe/>
6. Herman JL, Flores AR, O'Neill KK, et al. How many adults and youth identify as transgender in the United States? [homepage]. UCLA School of Law; 2022. Available from: <https://williamsinstitute.law.ucla.edu/publications/trans-adults-united-states/>
7. European Parliament. Sexual and reproductive health and rights in the EU, in the frame of women's health – P9_TA(2021)0314 [homepage]. European Parliament; 2021 Jun 24. Available from: https://www.europarl.europa.eu/doceo/document/TA-9-2021-0314_EN.html
8. Direção-Geral da Saúde. Estratégia de saúde para as pessoas lésbicas, gays, bissexuais, trans e intersexo – LGBTI. Vol. 1: promoção da saúde das pessoas trans e intersexo [Internet]. Lisboa: DGS; 2019. Available from: <https://apmgf.pt/wp-content/uploads/2023/06/i025699.pdf>
9. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.
10. Critical Appraisal Skills Programme. CASP qualitative checklist [Internet]. Oxford: CASP; 2018. Available from: https://casp-uk.net/images/checklist/documents/CASP-Qualitative-Studies-Checklist/CASP-Qualitative-Checklist-2018_fillable_form.pdf
11. National Institutes of Health. Quality assessment tool for observational cohort and cross-sectional studies [homepage]. London: NIH; 2021 Jul. Available from: <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools>
12. Haley SG, Tordoff DM, Kantor AZ, Crouch JM, Ahrens KR. Sex education for transgender and non-binary youth: previous experiences and recommended content. *J Sex Med*. 2019;16(11):1834-48.
13. Beswick A, Corkum M, D'Souza D. Locally advanced cervical cancer in a transgender man. *CMAJ*. 2019;191(3):E76-8.
14. Bentsianov S, Gordon L, Goldman A, Jacobs A, Steever J. Use of Copper intrauterine device in transgender male adolescents. *Contraception*. 2018;98(1):74-5.
15. Shires DA, Stroumsa D, Jaffee KD, Woodford MR. Primary care clinicians' willingness to care for transgender patients. *Ann Fam Med*. 2018;16(6):555-8.



16. Agénor M, Cottrill AA, Kay E, Janiak E, Gordon AR, Potter J. Contraceptive beliefs, decision making and care experiences among transmasculine young adults: a qualitative analysis. *Perspect Sex Reprod Health*. 2020;52(1):7-14.
17. Forsberg H, Eliason MJ. Healthcare providers' pregnancy prevention counseling of trans and non-binary assigned female at birth (TNB/AFAB) patients. *J Homosex*. 2022;69(2):356-83.
18. Nahata L, Chen D, Quinn GP, Travis M, Grannis C, Nelson E, et al. Reproductive attitudes and behaviors among transgender/nonbinary adolescents. *J Adolesc Health*. 2020;66(3):372-4.
19. Cipres D, Seidman D, Cloniger C 3rd, Nova C, O'Shea A, Obedin-Maliver J. Contraceptive use and pregnancy intentions among transgender men presenting to a clinic for sex workers and their families in San Francisco. *Contraception*. 2017;95(2):186-9.
20. Stark B, Hughto JM, Charlton BM, Deutsch MB, Potter J, Reisner SL. The contraceptive and reproductive history and planning goals of transmasculine adults: a mixed-methods study. *Contraception*. 2019;100(6):468-73.
21. Reynolds CA, Charlton BM. Sexual behavior and contraceptive use among cisgender and gender minority college students who were assigned female at birth. *J Pediatr Adolesc Gynecol*. 2021;34(4):477-83.
22. Gomez AM, D'Õ L, Ratliff GA, Crego PI, Hastings J. Contraceptive beliefs, needs, and care experiences among transgender and nonbinary young adults. *J Adolesc Health*. 2020;67(4):597-602.
23. Light A, Wang LF, Zeymo A, Gomez-Lobo V. Family planning and contraception use in transgender men. *Contraception*. 2018;98(4):266-9.
24. Vyas N, Douglas CR, Mann C, Weimer AK, Quinn MM. Access, barriers, and decisional regret in pursuit of fertility preservation among transgender and gender-diverse individuals. *Fertil Steril*. 2021;115(4):1029-34.
25. Tishelman AC, Sutter ME, Chen D, Sampson A, Nahata L, Kolbuck VD, et al. Health care provider perceptions of fertility preservation barriers and challenges with transgender patients and families: qualitative responses to an international survey. *J Assist Reprod Genet*. 2019;36(3):579-88.
26. Rahman M, Li DH, Moskowitz DA. Comparing the healthcare utilization and engagement in a sample of transgender and cisgender bisexual+ persons. *Arch Sex Behav*. 2019;48(1):255-60.
27. Chen D, Kolbuck VD, Sutter ME, Tishelman AC, Quinn GP, Nahata L. Knowledge, practice behaviors, and perceived barriers to fertility care among providers of transgender healthcare. *J Adolesc Health*. 2019;64(2):226-34.
28. Fix L, Durden M, Obedin-Maliver J, Moseson H, Hastings J, Stoeffler A, et al. Stakeholder perceptions and experiences regarding access to contraception and abortion for transgender, non-binary, and gender-expansive individuals assigned female at birth in the U.S. *Arch Sex Behav*. 2020;49(7):2683-702.
29. Deutsch MB. Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people [homepage]. 2nd ed. San Francisco: University of California-UCSF Transgender Care; 2016 Jun 17. Available from: <https://transcare.ucsf.edu/guidelines>
30. Weiselberg E. Menstrual considerations for transgender male and gender diverse adolescents who were assigned female at birth. *Curr Probl Pediatr Adolesc Health Care*. 2022;52(8):101239.
31. Becerra Pérez MM, Menear M, Brehaut JC, Légaré F. Extent and predictors of decision regret about health care decisions: a systematic review. *Med Decis Making*. 2016;36(6):777-90.
32. Wiercx K, Van Caenegem E, Pennings G, Elaut E, Dedecker D, Van de Peer F, et al. Reproductive wish in transsexual men. *Hum Reprod*. 2012;27(2):483-7.
33. Semlyen J, Kunasegaran K. Understanding barriers to cervical screening uptake in trans men: an exploratory qualitative analysis. *Lancet*. 2016;388 Suppl:104.
34. Direção-Geral da Saúde. Diagnóstico e estadiamento do cancro invasivo do colo do útero: norma n.º 018/2012, de 21/12/2012. Lisboa: DGS; 2012.
35. Santé Publique France. Baromètre santé 2010 [homepage]. Santé Publique France; 2016 Sep 27. Available from: <https://www.santepubliquefrance.fr/etudes-et-enquetes/barometres-de-sante-publique-france/barometre-sante-2010>
36. Subramaniam A, Fauci JM, Schneider KE, Whitworth JM, Erickson BK, Kim K, et al. Invasive cervical cancer and screening: what are the rates of unscreened and underscreened women in the modern era? *J Low Genit Tract Dis*. 2011;15(2):110-3.
37. Van Doorslaer E, Masseria C, Koolman X. Inequalities in access to medical care by income in developed countries. *CMAJ*. 2006;174(2):177-83.
38. Gifford DM, Underman K. The relationship between medical education and trans health disparities: a call to research. *Sociol Compass*. 2016;10(11):999-1013.
39. Van Gerwen OT, Jani A, Long DM, Austin EL, Musgrove K, Muzny CA. Prevalence of sexually transmitted infections and human immunodeficiency virus in transgender persons: a systematic review. *Transgend Health*. 2020;5(2):90-103.
40. Marshall Z, Welch V, Minichiello A, Swab M, Brunger F, Kaposy C. Documenting research with transgender, nonbinary, and other gender diverse (trans) individuals and communities: introducing the GlobalTrans Research Evidence Map. *Transgend Health*. 2019;4(1):68-80.

AUTHORS CONTRIBUTION

Conceptualization, SMF, AMP, and RAA; methodology, SMF, AMP, and RAA; software, SMF, AMP, and RAA; validation, SMF, AMP, and RAA; formal analysis, SMF, AMP, and RAA; investigation, SMF, AMP, and RAA; resources, SMF, AMP, and RAA; data curation, SMF, AMP, and RAA; writing – original draft, SMF, AMP, and RAA; writing - review & editing, SMF, AMP, and RAA; visualization, SMF, AMP, and RAA; supervision and project administration, SMF, AMP, and RAA.

CONFLITO DE INTERESSES

Os autores declaram não possuir quaisquer conflitos de interesse.

ENDEREÇO PARA CORRESPONDÊNCIA

Sílvia Martins Fernández

E-mail: silvia.martins.fernandez@gmail.com

<https://orcid.org/0000-0001-7367-6333>

Recebido em 30-10-2023

Aceite para publicação em 21-03-2024



ABSTRACT

SAÚDE SEXUAL E REPRODUTIVA NA POPULAÇÃO TRANSGÊNERO: UMA REVISÃO SISTEMÁTICA

Introdução: O acesso a cuidados de saúde sexuais e reprodutivos seguros e de alta qualidade faz parte dos direitos e bem-estar de todas as pessoas. Há uma escassez de diretrizes clínicas específicas para a população transgênero (TG).

Objetivo: Esta revisão sistemática pretende descrever a abordagem da saúde sexual da população TG.

Métodos: Foi realizada uma revisão sistematizada em duas bases de dados, MEDLINE e Scopus, seguindo os Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement. A qualidade dos estudos foi avaliada utilizando o Critical Appraisal Skills Programme Qualitative Checklist para estudos qualitativos e uma versão adaptada do Quality Assessment Tool for Cross-Sectional Studies. O protocolo foi registado na plataforma PROSPERO (CRD42022371962).

Resultados: Dos 671 artigos recuperados através da pesquisa, 13 cumpriram os critérios de inclusão e exclusão e foram selecionados para análise. Os fenómenos de interesse foram subdivididos em problemas relativos ao paciente e ao prestador de cuidados, contraceção, preservação da fertilidade e rastreio de cancro cervical. Os métodos contraceptivos podem ser usados com vista à prevenção da gravidez, tendo também impacto na disforia de género. Uma percentagem significativa dos utentes TG acredita que a testosterona pode ser usada como método contraceptivo, o que os impede de reconhecer o seu risco de engravidar. A escassez de educação formal dos profissionais de saúde neste tema, aliada à discriminação da população TG, contribui para o aumento dos mitos em saúde. A maioria dos TG deseja a parentalidade, não definindo preferência relativamente a filhos biológicos ou não. A realização de exame pélvico e rastreio do cancro cervical não é rotineira na população TG.

Conclusão: A presente revisão reforça a relevância e necessidade de desenvolver *guidelines* no âmbito da saúde sexual e reprodutiva da população TG. Os cuidados de saúde primários são de vital importância na gestão dos problemas de saúde desta população.

Palavras-chave: Planeamento familiar; Saúde reprodutiva; Cuidados de saúde primários; População transgênero.
